COMMUNIQUÉS West-GlobeNewswire

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
19/11/2025
Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses 1,2 Lunsumio subcutaneous offers [...]
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
19/11/2025
Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) ( [...]
BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth
19/11/2025
November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth. Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S [...]
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
19/11/2025
Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that its Board of Directors have decided to replace the current Restricted Share Unit (“RSU”) Plan [...]
ALX Oncology to Present at Upcoming Investor Conferences
18/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies [...]
NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
18/11/2025
Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles- [...]
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
18/11/2025
Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3 EPCORE [...]
Comprehensive Healthcare Takes Next Step Toward Expanding Access to Behavioral Healthcare in Central Washington
18/11/2025
Organization selected as one of 10 Certified Community Behavioral Health Clinic (CCBHC) pilot sites in the state YAKIMA, Wash., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Comprehensive Healthcare today announced that it was [...]
Capsa Healthcare to Showcase Integrated Central Fill Automation at ASHP Midyear 2025
18/11/2025
CANAL WINCHESTER, Ohio, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Capsa Healthcare, a leading innovator in medication management and pharmacy automation, will demonstrate its end-to-end pharmacy automation solutions at the 2025 [...]
UPDATE – PrognomiQ Launches ProVue Lung, a Proteomics-Based Laboratory Developed Test to Aid in the Early Detection of Lung Cancer
18/11/2025
– Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network – SAN MATEO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- PrognomiQ , a healthcare [...]
Rad Source Launches RS® 420 Q+ Boost & RS® 420 MAX – High-Capacity Cannabis Decontamination Solutions
18/11/2025
BUFORD, Ga., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rad Source Technologies, Inc. (Rad Source ® ), the global leader in x-ray-based cannabis decontamination, proudly announces the launch of two advanced systems: RS ® 420 Q+ [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18/11/2025
Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Suja Life Announces Confidential Submission of Draft Registration Statement
18/11/2025
OCEANSIDE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Suja Life, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs [...]
argenx Announces Results of Extraordinary General Meeting of Shareholders
18/11/2025
November 18, 2025 – 10:01 PM C ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, [...]
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility
18/11/2025
Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced their previously [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
18/11/2025
ZUG, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachment notification-of-managers-transaction- [...]
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
18/11/2025
IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago [...]
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer
18/11/2025
SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the [...]

Pages